In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on InfuSystem Holdings, with a price target of $15.00.
Hewitt covers the Healthcare sector, focusing on stocks such as Ligand Pharma, BioLife Solutions, and Maravai Lifesciences Holdings. According to TipRanks, Hewitt has an average return of -5.6% and a 37.94% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for InfuSystem Holdings with a $15.83 average price target.
Based on InfuSystem Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $36.23 million and a net profit of $2.04 million. In comparison, last year the company earned a revenue of $33.85 million and had a net profit of $933 thousand
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INFU in relation to earlier this year.
